Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Janssen Pharma bags breakthrough designation for niraparib in prostate cancer

      Janssen Pharma bags breakthrough designation for niraparib in prostate cancer

      Farhat Nasim6 Oct 2019 9:25 AM IST
      New Delhi: The Janssen Pharmaceutical Companies of Johnson & Johnson (JnJ) announced recently that the U.S. Food and Drug Administration (FDA) has...
      CDSCO approves SCTIMST as Medical Device Testing Lab

      CDSCO approves SCTIMST as Medical Device Testing Lab

      Farhat Nasim5 Oct 2019 3:16 PM IST
      New Delhi: Through a recent notification, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has given its approval to...
      Lupin Mandideep facility red-flagged by USFDA for CGMP violations

      Lupin Mandideep facility red-flagged by USFDA for CGMP violations

      Farhat Nasim5 Oct 2019 12:18 PM IST
      NEW DELHI: The US health regulator has red-flagged pharma firm Lupin for significant violations of the current good manufacturing practice regulations...
      SPARC neonatal seizures drug Phenobarbital gets Orphan Drug Designation from USFDA

      SPARC neonatal seizures drug Phenobarbital gets Orphan Drug Designation from USFDA

      Farhat Nasim5 Oct 2019 12:00 PM IST
      Orphan Drug Designation will grant seven years of US market exclusivity upon approval of Phenobarbital for the treatment of patients with neonatal...
      Lupin unveils generic version of CellCept in US

      Lupin unveils generic version of CellCept in US

      Farhat Nasim5 Oct 2019 9:30 AM IST
      Lupin Ltd's Mycophenolate Mofetil Capsules USP, 250 mg, is the generic version of Roche’s CellCept. Mumbai: Pharma major Lupin Limited (Lupin)...
      Health Ministry, WHO join hands to redesignate NHSRC for development of medical devices

      Health Ministry, WHO join hands to redesignate NHSRC for development of medical devices

      Farhat Nasim4 Oct 2019 5:06 PM IST
      This year in collaboration with WHO's country office, NHSRC developed a guidance document for the health ministry's free diagnostics initiative to...
      AstraZeneca auto-injector pen Fasenra for asthma treatment gets USFDA green light

      AstraZeneca auto-injector pen Fasenra for asthma treatment gets USFDA green light

      Farhat Nasim4 Oct 2019 1:42 PM IST
      Fasenra self-administration and the Fasenra Pen are already approved in the European Union and the drug is part of AstraZeneca’s newer class of...
      Alembic JV Aleor Derma gets USFDA nod for therapeutic equivalent of Clobex Spray

      Alembic JV Aleor Derma gets USFDA nod for therapeutic equivalent of Clobex Spray

      Farhat Nasim4 Oct 2019 12:40 PM IST
      Clobetasol Propionate Spray, 0.05% is indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA)...
      Sub-committee to align Drugs And Cosmetics, Magical Remedies Act to regulate Medical Advertisements: CDSCO Committee

      Sub-committee to align Drugs And Cosmetics, Magical Remedies Act to regulate Medical Advertisements: CDSCO Committee

      Farhat Nasim2 Oct 2019 11:48 AM IST
      New Delhi: The Drug Consultative Committee (DCC), functional under the apex drug regulatory body, Central Drug Standard Control Organisation (CDSCO)...
      Lupin clears Japanese regulator PMDA inspection of Goa facility

      Lupin clears Japanese regulator PMDA inspection of Goa facility

      Farhat Nasim2 Oct 2019 9:50 AM IST
      The Pharmaceutical and Medical Devices Agency (PMDA), Japan, has completed the Good Manufacturing Practice inspection of the company's Goa facility...
      4 websites get USFDA warning letter for selling illegal opioid medicines

      4 websites get USFDA warning letter for selling illegal opioid medicines

      Farhat Nasim2 Oct 2019 9:30 AM IST
      The networks which were issued the warning letters by USFDA and DEA on Monday for illegally marketing unapproved and misbranded versions of opioid...
      Pharmacokinetic study of Avastin: Cadila to submit revised protocol to CDSCO committee

      Pharmacokinetic study of Avastin: Cadila to submit revised protocol to CDSCO committee

      Farhat Nasim1 Oct 2019 4:09 PM IST
      New Delhi: The apex drug regulatory body, Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee (SEC) recently recommended...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok